Immunome (NASDAQ:IMNM) Shares Gap Up to $15.48

Immunome, Inc. (NASDAQ:IMNM)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $15.48, but opened at $16.06. Immunome shares last traded at $15.37, with a volume of 176,914 shares traded.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IMNM. Guggenheim began coverage on shares of Immunome in a research note on Monday, April 15th. They set a “buy” rating and a $35.00 price target on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Immunome in a research note on Monday, January 29th. SVB Leerink started coverage on shares of Immunome in a research note on Monday, January 29th. They set an “outperform” rating and a $30.00 price target on the stock. Finally, Wedbush boosted their price objective on Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a research report on Monday, April 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $32.67.

Immunome Price Performance

The company has a 50 day moving average price of $22.56 and a 200 day moving average price of $15.07. The firm has a market cap of $875.06 million, a PE ratio of -2.72 and a beta of 1.66.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.26). Immunome had a negative return on equity of 69.74% and a negative net margin of 761.92%. The company had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $3.40 million. On average, equities analysts anticipate that Immunome, Inc. will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunome

Several large investors have recently modified their holdings of the stock. Avidity Partners Management LP purchased a new position in Immunome in the fourth quarter worth $14,268,000. TD Asset Management Inc purchased a new position in Immunome in the third quarter worth $1,063,000. Mayo Clinic purchased a new position in Immunome in the fourth quarter worth $1,161,000. Cerity Partners LLC purchased a new position in Immunome in the fourth quarter worth $656,000. Finally, Emfo LLC acquired a new stake in Immunome in the fourth quarter valued at $633,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.